Cardiac catheter manufacturer CathRx Limited (CXD) today announced the John Hunter Hospital had joined its Australian clinical trial to gather data for Australian Therapeutic Goods Administration (TGA) approval for its quadrapolar and decapolar diagnostic catheters. John Hunter Hospital is a leading teaching hospital and major cardiology and cardiac surgery centre. CathRx’s Australian approval trial began at Westmead Hospital in Sydney in November 2008.
CathRx Chief Executive Officer Neil Anderson said that while the catheters had already been on sale in Europe, the Australian trial was being conducted to enable CathRx to file for Australian approvals. The protocol at John Hunter Hospital calls for use of CathRx’s diagnostic catheters undergoing electrophysiology procedures that require the use of diagnostic catheters. There will be an equal number of CathRx and control patients. The primary end-point is a confirmation of diagnostic capability.
CathRx is a medical device company which manufactures and sells advanced cardiac catheter systems for the treatment of cardiac arrhythmias. CathRx’s proprietary diagnostic and therapeutic catheters are designed to give physicians the tools to successfully treat patients with speed, safety and precision. CathRx’s first diagnostic products are now on sale in Europe.
Tags: CathRX, Clinical trials, CXD
